Ji Seok Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ji Seok Kim has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Anu Chittenden
19 shared publicationsBrian M. Wolpin
19 shared publicationsBrittany L. Bychkovsky
19 shared publicationsBruce E. Johnson
19 shared publicationsIsrael Gomy
19 shared publicationsJilliane Sotelo
19 shared publications
Latest Publications
- Open Access
Systematic Review of Quantitative Metrics to Standardize Contours on Radiotherapy Clinical Trials
Radiation therapy quality assurance (RTQA) is critical to the success of RT and impacts trial outcomes. We aimed to evaluate the existence of standardized quantitative metrics to grade contours as part of RTQA and to identify barriers to standardization. A systematic review was conducted according to PRISMA guidelines. PubMed, Web of Science, and Embase were used to search relevant studies published from 2014–2024. Our endpoints were quantitative metrics used to guide contour scoring. We initially planned quantitative synthesis (meta-analysis) of geometric metric distributions across studies. However, the heterogeneity in evaluation methods, predominance of qualitative assessment, and lack of standardized reporting precluded meaningful quantitative pooling. We therefore performed structured qualitative synthesis, thematic analysis, and gap assessment. A total of 37 studies were included, 20 of which were prospective and 17 were retrospective. Of the prospective, 12 reported the results of benchmark case/dummy run reviews, 4 were a combination of benchmark case/dummy runs and individual QA analyses done pre- or post-treatment, 1 used knowledge-based planning to evaluate plans in real-time, and 3 involved real-time prospective QA. Only one reported the use of an objective QA scoring system. There is a concerning lack of standardized quantitative metrics to evaluate RT contours on clinical trials and a lack of methodological consistency required for systematic quantitative synthesis, reinforcing the need for standardization. Effort is needed to create guidelines for quantitatively evaluating RT contours to use across clinical trials to improve the quality and validity of RTQA.
Open AccessSystematic Review of Quantitative Metrics to Standardize Contours on Radiotherapy Clinical Trials
Radiation therapy quality assurance (RTQA) is critical to the success of RT and impacts trial outcomes. We aimed to evaluate the existence of standardized quantitative metrics to grade contours as part of RTQA and to identify barriers to standardization. A systematic review was conducted according to PRISMA guidelines. PubMed, Web of Science, and Embase were used to search relevant studies published from 2014–2024. Our endpoints were quantitative metrics used to guide contour scoring. We initially planned quantitative synthesis (meta-analysis) of geometric metric distributions across studies. However, the heterogeneity in evaluation methods, predominance of qualitative assessment, and lack of standardized reporting precluded meaningful quantitative pooling. We therefore performed structured qualitative synthesis, thematic analysis, and gap assessment. A total of 37 studies were included, 20 of which were prospective and 17 were retrospective. Of the prospective, 12 reported the results of benchmark case/dummy run reviews, 4 were a combination of benchmark case/dummy runs and individual QA analyses done pre- or post-treatment, 1 used knowledge-based planning to evaluate plans in real-time, and 3 involved real-time prospective QA. Only one reported the use of an objective QA scoring system. There is a concerning lack of standardized quantitative metrics to evaluate RT contours on clinical trials and a lack of methodological consistency required for systematic quantitative synthesis, reinforcing the need for standardization. Effort is needed to create guidelines for quantitatively evaluating RT contours to use across clinical trials to improve the quality and validity of RTQA.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Purpose:Tumor-only genomic testing can uncover somatic and germline pathogenic variants [pathogenic/likely pathogenic (P/LP)] in cancer predisposition genes. We describe the prevalence of P/LPs in BRCA1/2 and PALB2 (B1B2P2) across malignancies and the frequency of clinical germline testing (CGT) in patients with P/LPs in B1B2P2 identified on tumor-only testing.Experimental Design:Among 7,575 patients with cancer tested between 2016 and 2018 with the OncoPanel tumor-only sequencing assay, we characterized P/LP frequencies by tumor type, receipt of CGT prior to or within 12 months after OncoPanel, and factors associated with CGT.Results:272 (3.6%) patients had OncoPanel-detected P/LPs in B1B2P2: 37.5% of P/LPs were in BRCA-related cancers; the remainder were in non-BRCA tumors. P/LPs were detected in ≥5% of breast, pancreatic, prostate, ovarian, nonmelanoma skin, endometrial, small cell lung, and colorectal cancers. 37.9% of patients with P/LPs received CGT prior to OncoPanel; an additional 10.7% underwent CGT within 12 months of OncoPanel. Among 132 with CGT, 88.6% had ≥1 clinical factor for CGT compared with 47.1% who did not undergo CGT. Patients with BRCA tumors were more likely to have CGT compared with those without (81.4% vs. 29.0%, P < 0.0001). Among patients with CGT, 70.5% (93/132) of P/LPs were germline.Conclusions:Tumor-only genomic testing identified P/LPs in B1B2P2 in 3.6% of patients. 52.9% of patients with tumor-detected P/LPs and without CGT did not meet personal or family history criteria for CGT. In addition, some patients with tumor-detected P/LPs were not referred for CGT, especially those with non-BRCA tumors. Given implications for treatment selection and familial cancer risk, processes to reliably trigger CGT from tumor-genomic findings are needed.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Purpose:Tumor-only genomic testing can uncover somatic and germline pathogenic variants [pathogenic/likely pathogenic (P/LP)] in cancer predisposition genes. We describe the prevalence of P/LPs in BRCA1/2 and PALB2 (B1B2P2) across malignancies and the frequency of clinical germline testing (CGT) in patients with P/LPs in B1B2P2 identified on tumor-only testing.Experimental Design:Among 7,575 patients with cancer tested between 2016 and 2018 with the OncoPanel tumor-only sequencing assay, we characterized P/LP frequencies by tumor type, receipt of CGT prior to or within 12 months after OncoPanel, and factors associated with CGT.Results:272 (3.6%) patients had OncoPanel-detected P/LPs in B1B2P2: 37.5% of P/LPs were in BRCA-related cancers; the remainder were in non-BRCA tumors. P/LPs were detected in ≥5% of breast, pancreatic, prostate, ovarian, nonmelanoma skin, endometrial, small cell lung, and colorectal cancers. 37.9% of patients with P/LPs received CGT prior to OncoPanel; an additional 10.7% underwent CGT within 12 months of OncoPanel. Among 132 with CGT, 88.6% had ≥1 clinical factor for CGT compared with 47.1% who did not undergo CGT. Patients with BRCA tumors were more likely to have CGT compared with those without (81.4% vs. 29.0%, P < 0.0001). Among patients with CGT, 70.5% (93/132) of P/LPs were germline.Conclusions:Tumor-only genomic testing identified P/LPs in B1B2P2 in 3.6% of patients. 52.9% of patients with tumor-detected P/LPs and without CGT did not meet personal or family history criteria for CGT. In addition, some patients with tumor-detected P/LPs were not referred for CGT, especially those with non-BRCA tumors. Given implications for treatment selection and familial cancer risk, processes to reliably trigger CGT from tumor-genomic findings are needed.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program